Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

NEXT STORY
Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome
PREV STORY
Global $31Bn+ Respiratory Care Devices Market Outlook, 2024 – Growing Demand for Home Care Therapeutic Devices
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

author_avatar
NASDAQ Market News

India Molecular Diagnostics Market to 2026 by Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing) & Technology (PCR, In-situ Hybridization, Chips & Microarrays)

author_avatar
NASDAQ Market News

TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

author_avatar
NASDAQ Market News